STAND NUMBER: N296
GTX medical B.V.
GTX developed a therapy to make paralyzed people walk again after a spinal cord injury (SCI), based on the research conducted by Professor Grégoire Courtine at EPFL and Professor Jocelyne Bloch at CHUV in Lausanne (CH). The innovation, called Targeted Epidural Spinal Stimulation (TESS), consists of an implantable paddle lead, an implantable pulse generator and external components combined with intensive rehabilitation. TESS facilitates the reorganisation of neural pathways and repairs the connection between the brain, spine and lower limits, potentially improving other symptoms related to spinal cord injuries.
GTX is a privately held company established in 2014 with headquarters in Eindhoven, The Netherlands and offices in Lausanne, Switzerland.
Worldwide, more than a thousand people every day become victim of a spinal cord injury (SCI). The consequences are devastating for those affected as their lives are completely turned upside down.
The brain controls the limbs and internal processes such as breathing, blood circulation and digestion via the spinal cord. If this information highway of our body is injured, the transfer of information no longer works, or only works in part, potentially leading to paralysis of the legs and arms, depending on the location and extent of the damage to the spinal cord.
At the EPFL in Lausanne, Professor Grégoire Courtine has been studying recovery mechanisms after SCI, a condition that was once associated with a high mortality rate. He developed a treatment that has enabled people with SCI to walk again. The approach relies on the reactivation and strengthening of spared fibres across the lesion and is enabled by electrical spinal cord stimulation delivered through an implant combined with an intense rehabilitation program. The technology therefore has the potential to restore spinal cord function and thus improve the recovery of patients.
GTX medical was found to turn these findings into a therapy available to people with a SCI.
In developing new innovations, the GTX medical team focuses on a new treatment, targeted epidural spinal stimulation (TESS), which is based on the research conducted by Professor Grégoire Courtine at EPFL and Professor Jocelyne Bloch at CHUV in Lausanne. Both demonstrated that the delivery of electrical stimulation targeting the individual roots of the spinal cord amplifies the residual commands from the brain, which enables people with severe spinal cord injuries to regain control over specific leg muscles. Combined with an intensive rehabilitation programme, this enables voluntary control of paralysed leg muscles. These results have been published in Science, Nature and Nature Neuroscience. The GTX team is developing Go-2, a completely new set of proprietary neuro-technologies to restore leg motor control.
The objectives of GTX are to remain the leading company in neurostimulation for spinal cord injuries and to give back the ability to walk to people with SCI